Related Experiment Videos
Comparative in vitro activity of FK-037, a new cephalosporin antibiotic
A M Clarke1, S J Zemcov, M M Hubinette
1Division of Medical Microbiology, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Abstract:
The in vitro activity of FK-037, a novel parenteral oxime-type cephalosporin, was compared with that of cefepime, cefpirome, ceftazidime, imipenem, and gentamicin against a total of 668 recent clinical isolates. Minimum inhibitory concentrations were determined by a standard agar dilution procedure, and all isolates were tested at two inocula (10(4) and 10(6) colony forming units). FK-037 inhibited 90% of isolates of Escherichia coli, Klebsiella species, Proteus mirabilis, P. vulgaris, Morganella morganii, Serratia marcescens, Providencia stuartii, Citrobacter freundii, Salmonella typhi, Shigella sonnei, Yersinia enterocolitica, Aeromonas species, and Haemophilus influenzae at < or = 1 microgram/ml. FK-037 was less active against Enterobacter species, Acinetobacter species, and Pseudomonas species, requiring 16 micrograms/ml to inhibit 90% of isolates, and was inactive against Xanthomonas maltophilia. FK-037 inhibited 90% of methicillin-susceptible Staphylococcus aureus at < or = 1 microgram/ml and 90% of methicillin-resistant S. aureus at < or = 8 micrograms/ml.
Insights
FK-037, a new cephalosporin antibiotic, shows potent in vitro activity against many common Gram-negative and Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. Its efficacy against certain challenging pathogens like Pseudomonas species warrants further investigation.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- The emergence of antibiotic resistance necessitates the development of novel antimicrobial agents.
- Oxime-type cephalosporins represent a class of antibiotics with broad-spectrum activity.
- Understanding the in vitro efficacy of new agents against contemporary clinical isolates is crucial for guiding therapeutic strategies.
Purpose of the Study:
- To evaluate the in vitro antibacterial activity of FK-037, a novel parenteral oxime-type cephalosporin.
- To compare the activity of FK-037 with established antibiotics, including cefepime, cefpirome, ceftazidime, imipenem, and gentamicin.
- To assess FK-037's efficacy against a diverse collection of recent clinical bacterial isolates.
Main Methods:
- Minimum inhibitory concentrations (MICs) were determined using a standard agar dilution method.
- A total of 668 recent clinical bacterial isolates were tested.
- Isolates were challenged with two different inoculum sizes (10^4 and 10^6 colony-forming units/mL).
Main Results:
- FK-037 demonstrated potent activity (MIC90 ≤ 1 µg/mL) against a wide range of Gram-negative bacteria, including Escherichia coli, Klebsiella spp., and Haemophilus influenzae.
- The drug exhibited significant activity against methicillin-susceptible Staphylococcus aureus (MIC90 ≤ 1 µg/mL) and moderate activity against methicillin-resistant S. aureus (MIC90 ≤ 8 µg/mL).
- FK-037 showed reduced activity against Enterobacter spp., Acinetobacter spp., and Pseudomonas spp. (MIC90 = 16 µg/mL) and was inactive against Xanthomonas maltophilia.
Conclusions:
- FK-037 possesses broad-spectrum in vitro activity against many clinically relevant Gram-negative and Gram-positive pathogens.
- Its activity profile suggests potential utility as a parenteral antibiotic, particularly against susceptible Gram-negative bacteria and S. aureus.
- Further clinical evaluation is warranted to determine FK-037's therapeutic role, especially considering its limitations against certain resistant organisms.